Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing E. coli

被引:6
作者
Handal, Nina [1 ]
Whitworth, Jimmy [2 ]
Lyngbakken, Magnus Nakrem [3 ,4 ]
Berdal, Jan Erik [3 ,4 ]
Dalgard, Olav [3 ,4 ]
Jorgensen, Silje Bakken [1 ,5 ]
机构
[1] Akershus Univ Hosp, Dept Microbiol & Infect Control, Div Diagnost & Technol, Lorenskog, Norway
[2] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England
[3] Akershus Univ Hosp, Dept Infect Dis, Div Med, Lorenskog, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
[5] Akershus Univ Hosp, Dept Emergency Med, Div Internal Med, Lorenskog, Norway
关键词
Extended-spectrum beta-lactamases (ESBL); bloodstream infection; mortality; Enterobacterales; antimicrobial resistance; healthcare associated infection; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; ESCHERICHIA-COLI; BACTEREMIA; OUTCOMES; EPIDEMIOLOGY; VALIDATION; RESISTANCE; THERAPY;
D O I
10.1080/23744235.2023.2261538
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare mortality and length of hospital stay between patients with ESBL-producing E. coli bloodstream infections (BSIs) and patients with non-ESBL E. coli BSIs. We also aimed at describing risk factors for ESBL-producing E. coli BSIs and time to effective antibiotic treatment for the two groups.Methods: A retrospective case-control study among adults admitted between 2014 and 2021 to a Norwegian University Hospital.Results: A total of 468 E. coli BSI episodes from 441 patients were included (234 BSIs each in the ESBL- and non-ESBL group). Among the ESBL-producing E. coli BSIs, 10.9% (25/230) deaths occurred within 30 days compared to 9.0% (21/234) in the non-ESBL group. The adjusted 30-day mortality OR was 1.6 (95% CI 0.7-3.7, p = 0.248). Effective antibiotic treatment was administered within 24 hours to 55.2% (129/234) in the ESBL-group compared to 86.8% (203/234) in the non-ESBL group. Among BSIs of urinary tract origin (n = 317), the median length of hospital stay increased by two days in the ESBL group (six versus four days, p < 0.001). No significant difference in the length of hospital stay was found for other sources of infection (n = 151), with a median of seven versus six days (p = 0.550) in the ESBL- and non-ESBL groups, respectively.Conclusion: There was no statistically significant difference in 30-day mortality in ESBL-producing E. coli compared to non-ESBL E. coli BSI, despite a delay in the administration of an effective antibiotic in the former group. ESBL-production was associated with an increased length of stay in BSIs of urinary tract origin.
引用
收藏
页码:19 / 31
页数:13
相关论文
共 50 条
[41]   ESBL-producing-multidrug resistant E. coli population from urinary tract infections is less diverse than non-ESBL-multidrug resistant population [J].
Arana, David M. ;
Sanchez, Aida ;
Bautista, Veronica ;
Oteo-Iglesias, Jesus ;
Alos, Juan-Ignacio .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2019, 37 (10) :652-655
[42]   Controversies over the management of infections caused by Amp-C- and ESBL-producing Enterobacterales: what questions remain for future studies? [J].
Burillo, Almudena ;
Bouza, Emilio .
CURRENT OPINION IN INFECTIOUS DISEASES, 2022, 35 (06) :575-582
[43]   An identification protocol for ESBL-producing Gram-negative bacteria bloodstream infections using a MinION nanopore sequencer [J].
Sakai, Jun ;
Tarumoto, Norihito ;
Kodana, Masahiro ;
Ashikawa, Sae ;
Imai, Kazuo ;
Kawamura, Toru ;
Ikebuchi, Kenji ;
Murakami, Takashi ;
Mitsutake, Kotaro ;
Maeda, Takuya ;
Maesaki, Shigefumi .
JOURNAL OF MEDICAL MICROBIOLOGY, 2019, 68 (08) :1219-1226
[44]   Infections caused by extended-spectrum β-lactamase-producing Enterobacterales after rectal colonization with ESBL-producing Escherichia coli or Klebsiella pneumoniae [J].
Denkel, L. A. ;
Maechler, F. ;
Schwab, F. ;
Kola, A. ;
Weber, A. ;
Gastmeier, P. ;
Paeffflin, F. ;
Weber, S. ;
Werner, G. ;
Pfeifer, Y. ;
Pietsch, M. ;
Leistner, R. .
CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (08) :1046-1051
[45]   Appropriateness of empirical antibiotic prescription for bloodstream infections in an emergency department from 2006 to 2018: impact of the spread of ESBL-producing Enterobacterales [J].
Clemenceau, Marie ;
Ahmed-Elie, Samira ;
Vilfaillot, Aurelie ;
Chocron, Richard ;
Compain, Fabrice ;
Lebeaux, David ;
Grohs, Patrick .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (01) :71-77
[46]   ESBL-Producing Escherichia coli Isolated from Bloodstream Infections - Antimicrobial Susceptibility, Conjugative Transfer of Resistance Genes and Phylogenetic Origin [J].
Franiczek, Roman ;
Krzyzanowska, Barbara .
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 23 (06) :865-870
[47]   Comparative analysis of virulence-associated genes in ESBL-producing Escherichia coli isolates from bloodstream and urinary tract infections [J].
Tanaka, Mayuko ;
Hanawa, Tomoko ;
Suda, Tomoya ;
Tanji, Yasunori ;
Minh, Le Nhat ;
Kondo, Kohei ;
Azam, Aa Haeruman ;
Kiga, Kotaro ;
Yonetani, Shota ;
Yashiro, Ryu ;
Ohmori, Takuya ;
Matsuda, Takeaki .
FRONTIERS IN MICROBIOLOGY, 2025, 16
[48]   Persistence of MRSA and ESBL-producing E . coli and K . oxytoca in river water [J].
Essert, Sarah M. ;
Zacharias, Nicole ;
Precht, Tabea ;
Pankratz, Debbie ;
Funken, Karolin ;
Mutters, Nico T. ;
Kistemann, Thomas ;
Schreiber, Christiane .
HYGIENE AND ENVIRONMENTAL HEALTH ADVANCES, 2023, 7
[49]   In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial [J].
Stewart, Adam G. ;
Cottrell, Kyra ;
Henderson, Andrew ;
Vemuri, Kanthi ;
Bauer, Michelle J. ;
Paterson, David L. ;
Harris, Patrick N. A. .
MICROBIOLOGY SPECTRUM, 2021, 9 (01) :1-6
[50]   Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum β-lactamase (ESBL)-producing versus non-ESBL-producing Escherichia coli in a hollow-fibre infection model [J].
Islam, Kamrul ;
Sime, Fekade B. ;
Bauer, Michelle J. ;
Forde, Brian M. ;
Wallis, Steven C. ;
Harris, Patrick ;
Naicker, Saiyuri ;
Shirin, Tahmina ;
Habib, Zakir H. ;
Flora, Meerjady S. ;
Roberts, Jason A. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (02)